查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1618226

关节疼痛注射市场机会、成长动力、产业趋势分析与预测 2024 - 2032

Joint Pain Injections Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 180 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年，全球关节止痛注射市场估值为36亿美元，预计2024年至2032年将以7.7%的年复合成长率(CAGR)增长。的发展。市面上依注射类型分为透明质酸注射液、皮质类固醇注射液、富血小板血浆注射液。 2023年，透明质酸注射剂以64.8%的收入份额主导市场，预计在预测期内复合年增长率将达到7.9%。人口老化和创新产品的推出相结合预计将推动市场成长。

人们越来越喜欢能够快速获得临床结果的微创手术，这进一步增加了对透明质酸注射的需求。这些注射剂主要用于治疗膝骨关节炎，并因其透过称为黏性补充的方法改善关节功能的能力而受到认可。关节疼痛注射市场也按关节类型分类，包括膝关节、肩肘关节、踝关节、髋关节以及其他关节。膝关节领域预计将经历显着增长，预测显示在分析期间将达到 27 亿美元。

这种激增主要是由于膝关节相关疾病的高盛行率造成的，特别是骨关节炎，其特征是软骨和骨骼逐渐恶化。作为老年人的常见疾病，骨关节炎会导致不适和活动受限。标准治疗选择通常包括物理治疗、復健、非类固醇类抗发炎药物和透明质酸黏稠补充，这强调了关节疼痛注射在控制这些病症中的重要性。从区域分析来看，北美地区在 2023 年占据最大的市场份额，达到 47.4%，预计未来几年将大幅成长。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 36 亿美元
预测值 72 亿美元
复合年增长率 7.7%

这种主导地位主要归因于关节炎和其他骨科疾病发病率的上升，以及先进治疗方案的快速采用。老化人口中关节疾病的盛行率不断上升，加上运动和事故造成的伤害增加，以及治疗解决方案的持续创新，是推动该地区市场成长的重要因素。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 骨科疾病盛行率不断上升
      • 技术进步
      • 膝盖疼痛注射的需求不断增加
      • 缓解关节疼痛和发炎的治疗优势
    • 产业陷阱与挑战
      • 关节疼痛注射费用高
      • 与关节疼痛注射相关的副作用
  • 成长潜力分析
  • 技术景观
    • 干细胞疗法
    • 微创手术
  • 管道分析
  • 监管环境
    • 我们
    • 欧洲
  • 未来市场趋势
  • 关节疼痛流行病学情景
  • 报销场景
  • 2023 年定价分析
  • 差距分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
    • 全球的
    • 北美洲
    • 欧洲
    • 亚太地区
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按註射类型，2018 年 - 2032 年

  • 主要趋势
  • 玻尿酸注射液
  • 皮质类固醇注射
  • 富血小板血浆注射

第 6 章：市场估计与预测：按联合类型，2018 年 - 2032 年

  • 主要趋势
  • 膝盖
  • 肩部和肘部
  • 脚踝和臀部
  • 其他接头类型

第 7 章：市场估计与预测：依最终用途，2018 年 - 2032 年

  • 主要趋势
  • 医院
  • 诊所
  • 其他最终用途

第 8 章：市场估计与预测：按地区划分，2018 年 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 9 章：公司简介

  • Anika Therapeutics, Inc.
  • Arthrex
  • Bioventus
  • Emcyte Corporation
  • Ferring BV
  • Lifecore Biomedical
  • OrthogenRx
  • Pacira BioSciences (Flexion)
  • Pfizer, Inc.
  • Sanofi SA
  • Stryker Corporation
  • Zimmer Biomet Holdings, Inc.
简介目录
Product Code: 5403

The Global Joint Pain Injections Market was valued at USD 3.6 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2032. The increasing elderly population and the rising incidence of orthopedic conditions drive this market's expansion. The market is divided by injection type into hyaluronic acid injections, corticosteroid injections, and platelet-rich plasma injections. In 2023, hyaluronic acid injections dominated the market with a 64.8% revenue share and are expected to experience a notable CAGR of 7.9% during the forecast period. The combination of an aging demographic and the introduction of innovative products is anticipated to boost market growth.

There is a growing preference for minimally invasive procedures that deliver rapid clinical outcomes, further enhancing the demand for hyaluronic acid injections. These injections are primarily used for treating knee osteoarthritis and are recognized for their ability to improve joint function through a method known as viscosupplementation. The joint pain injections market is also categorized by joint type, including knee, shoulder and elbow, ankle, and hip, as well as other joints. The knee segment is expected to experience significant growth, with projections indicating it will reach USD 2.7 billion during the analysis period.

This surge is largely driven by the high prevalence of knee-related disorders, particularly osteoarthritis, characterized by the gradual deterioration of cartilage and bone. As a common ailment among the elderly, osteoarthritis leads to discomfort and restricted mobility. Standard treatment options often include physical therapy, rehabilitation, non-steroidal anti-inflammatory drugs, and viscosupplementation with hyaluronic acid, underscoring the importance of joint pain injections in managing these conditions. In terms of regional analysis, North America held the largest market share at 47.4% in 2023, with substantial growth anticipated in the upcoming years.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$3.6 Billion
Forecast Value$7.2 Billion
CAGR7.7%

This dominance is primarily attributed to the rising incidence of arthritis and other orthopedic disorders, alongside the swift adoption of advanced treatment options. The growing prevalence of joint conditions among the aging population, in line with an increase in injuries from sports and accidents, as well as continuous innovation in therapeutic solutions, are vital factors driving market growth in this region.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing prevalence of orthopedic diseases
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Rising demand for knee pain injections
      • 3.2.1.4 Therapeutics advantages to relieve joint pain & inflammation
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of joint pain injections
      • 3.2.2.2 Side effects associated with joint pain injections
  • 3.3 Growth potential analysis
  • 3.4 Technological landscape
    • 3.4.1 Stem cell therapy
    • 3.4.2 Minimally invasive procedures
  • 3.5 Pipeline analysis
  • 3.6 Regulatory landscape
    • 3.6.1 U.S.
    • 3.6.2 Europe
  • 3.7 Future market trends
  • 3.8 Joint pain epidemiology scenario
  • 3.9 Reimbursement scenario
  • 3.10 Pricing analysis, 2023
  • 3.11 Gap analysis
  • 3.12 Porter's analysis
  • 3.13 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
    • 4.3.1 Global
    • 4.3.2 North America
    • 4.3.3 Europe
    • 4.3.4 Asia Pacific
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Injection Type, 2018 - 2032 ($ Mn and Units)

  • 5.1 Key trends
  • 5.2 Hyaluronic acid injections
  • 5.3 Corticosteroid injections
  • 5.4 Platelet rich plasma injections

Chapter 6 Market Estimates and Forecast, By Joint Type, 2018 - 2032 ($ Mn and Units)

  • 6.1 Key trends
  • 6.2 Knee
  • 6.3 Shoulder & elbow
  • 6.4 Ankle & hip
  • 6.5 Other joint types

Chapter 7 Market Estimates and Forecast, By End Use, 2018 - 2032 ($ Mn and Units)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Clinics
  • 7.4 Other End Use

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn and Units)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Anika Therapeutics, Inc.
  • 9.2 Arthrex
  • 9.3 Bioventus
  • 9.4 Emcyte Corporation
  • 9.5 Ferring B.V.
  • 9.6 Lifecore Biomedical
  • 9.7 OrthogenRx
  • 9.8 Pacira BioSciences (Flexion)
  • 9.9 Pfizer, Inc.
  • 9.10 Sanofi S.A.
  • 9.11 Stryker Corporation
  • 9.12 Zimmer Biomet Holdings, Inc.